These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 26014957)
1. Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age. Cirillo I; Vaccaro N; Castaneda-Ruiz B; Redman R; Cossey V; Bradley JS; Allegaert K Antimicrob Agents Chemother; 2015 Aug; 59(8):4742-9. PubMed ID: 26014957 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. Cirillo I; Vaccaro N; Turner K; Solanki B; Natarajan J; Redman R J Clin Pharmacol; 2009 Jul; 49(7):798-806. PubMed ID: 19553404 [TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections. Lee DH; Kim YK; Jin K; Kang MJ; Joo YD; Kim YW; Moon YS; Shin JG; Kiem S Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223378 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis. Cirillo I; Vaccaro N; Redman R; Black PL; Kearns GL J Clin Pharmacol; 2012 Nov; 52(11):1645-53. PubMed ID: 22174436 [TBL] [Abstract][Full Text] [Related]
5. Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. Cirillo I; Mannens G; Janssen C; Vermeir M; Cuyckens F; Desai-Krieger D; Vaccaro N; Kao LM; Devineni D; Redman R; Turner K Antimicrob Agents Chemother; 2008 Oct; 52(10):3478-83. PubMed ID: 18644951 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Chastre J; Wunderink R; Prokocimer P; Lee M; Kaniga K; Friedland I Crit Care Med; 2008 Apr; 36(4):1089-96. PubMed ID: 18379232 [TBL] [Abstract][Full Text] [Related]
7. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665 [TBL] [Abstract][Full Text] [Related]
8. Elimination of Doripenem during Dialysis and Pharmacokinetic Evaluation of Posthemodialysis Dosing for Patients Undergoing Intermittent Renal Replacement Therapy. Vossen MG; Ehmann L; Pferschy S; Maier-Salamon A; Haidinger M; Weiser C; Wenisch JM; Saria K; Kajahn C; Jilch S; Lemmerer R; Bécède M; Zeitlinger M; Kloft C; Jäger W; Thalhammer F Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530855 [TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of doripenem in Japanese subjects and Monte-Carlo simulation for patients with renal impairment. Matsuo Y; Ishibashi T; Kubota R; Wajima T J Infect Chemother; 2015 Feb; 21(2):123-9. PubMed ID: 25487084 [TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia. Jaruratanasirikul S; Wongpoowarak W; Kositpantawong N; Aeinlang N; Jullangkoon M Int J Antimicrob Agents; 2012 Nov; 40(5):434-9. PubMed ID: 22959555 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumonia. Harada M; Inui N; Suda T; Nakamura Y; Wajima T; Matsuo Y; Chida K Int J Antimicrob Agents; 2013 Aug; 42(2):149-54. PubMed ID: 23684002 [TBL] [Abstract][Full Text] [Related]
15. Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. Cirillo I; Vaccaro N; Balis D; Redman R; Matzke GR Antimicrob Agents Chemother; 2011 Mar; 55(3):1187-93. PubMed ID: 21199922 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic modeling and simulation for dose rationale of doripenem in neonates and infants. Matsuo Y; Matsumoto S; Wajima T; Matsubara K Drug Metab Pharmacokinet; 2020 Feb; 35(1):145-150. PubMed ID: 31969257 [TBL] [Abstract][Full Text] [Related]
17. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis. Sunzel M; Learoyd M; Li J; Li Y; Ngo N; Edeki T Int J Antimicrob Agents; 2015 Dec; 46(6):682-8. PubMed ID: 26545441 [TBL] [Abstract][Full Text] [Related]